PB2089: IN-CLASS TRANSITION FROM PARENTERAL BORTEZOMIB TO ORAL IXAZOMIB IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) ACCORDING TO AGE AND FRAILTY STATUS: UPDATED SUBGROUP ANALYSIS OF US MM-6
Saulius K. Girnius,
Joshua Richter,
Roger M. Lyons,
Kimberly Bogard,
Sudhir Manda,
Ruemu E. Birhiray,
Habte A. Yimer,
Kim Tran,
Suman Kambhampati,
Jyoti Arora,
Stephen Noga,
Robert Rifkin
Affiliations
Saulius K. Girnius
1 Trihealth Cancer Institute, Cincinnati, OH, United States
Joshua Richter
2 Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, United States
Roger M. Lyons
3 Texas Oncology/US Oncology Research, San Antonio, TX, United States
Kimberly Bogard
4 Takeda Pharmaceuticals U.S.A., Inc., Lexington, MA, United States
Sudhir Manda
5 Arizona Oncology/US Oncology Research, Tucson, AZ, United States
Ruemu E. Birhiray
6 Hematology Oncology of Indiana/American Oncology Network, Indianapolis, IN, United States
Habte A. Yimer
7 Texas Oncology/US Oncology Research, Tyler, TX, United States
Kim Tran
4 Takeda Pharmaceuticals U.S.A., Inc., Lexington, MA, United States
Suman Kambhampati
8 Kansas City Veterans Affairs Medical Center, Kansas City, MO, United States
Jyoti Arora
9 Takeda Pharmaceuticals U.S.A., Inc., Lexington, MA, United States
Stephen Noga
9 Takeda Pharmaceuticals U.S.A., Inc., Lexington, MA, United States
Robert Rifkin
10 Rocky Mountain Cancer Centers/US Oncology Research, Denver, CO, United States
